All In Biotech

Drug Trial Radar · NCT05795595

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Mar 13, 2023

Primary completion

Sep 18, 2025

Study completion Sep 18, 2025

Sponsor

Lead sponsor
CRISPR Therapeutics AGIndustry
Sponsor type
Industry
First posted
Apr 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.

Conditions

  • Clear Cell Renal Cell Carcinoma
  • Cervical Carcinoma
  • Esophageal Carcinoma
  • Pancreatic Adenocarcinoma
  • Malignant Pleural Mesothelioma

Interventions

  • CTX131Biological

    CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 (Dose Escalation): Incidence of adverse eventsTime frame: From CTX131 infusion up to 28 days post-infusion
  2. Phase 2 (Cohort Expansion): Objective response rate (ORR)Time frame: From CTX131 infusion up to 60 months post-infusion

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site 3

    Duarte, California

  • Research Site 7

    Chicago, Illinois

  • Research Site 6

    Boston, Massachusetts

  • Research Site 2

    St Louis, Missouri

  • Research Site 4

    Durham, North Carolina

  • Research Site 1

    Nashville, Tennessee

  • Research Site 5

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.